Remove Production Remove Small Molecule Remove Synthetic Chemistry
article thumbnail

Re-Imagining Med Chem Strategies: the Tyranny of the n+1 Compound

DrugBaron

Finding small molecule drugs is much harder than finding a needle in a haystack – discovering the right arrangement of atoms to bind precisely to a protein target to elicit a particular response is a problem of vast dimensionality. Yet the situation with small molecules is even worse.

article thumbnail

Part 2 Chemistry Webinar Series: Remote Access Robotic Controlled Compound Synthesis - Recap

The Strateos Blog: Drug Discovery

In continued efforts to provide scientists with end-to-end technologies to accelerate their workflows, Strateos has expanded its synthetic chemistry solutions with the integration of PerkinElmer Informatics Signals™ electronic lab notebook (ELN). Ben Miles, Ph.D., Ben Miles, Ph.D.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Following our pole star to a transformative collaboration

Dark Matter Blog

All of that, of course, bodes well for a productive long-term relationship. Our Chinese CROs are back online and doing synthetic chemistry at a pre-pandemic pace. Our ambition was to unlock vast swaths of valuable biology inaccessible to medicine today because the proteins involved elude our reach.

RNA 52
article thumbnail

AWS helps Pfizer accelerate drug development and clinical manufacturing

The Pharma Data

AWS is working with Pfizer to develop a prototype solution for detecting abnormal data points in its drug product continuous clinical manufacturing platform for solid oral-dose medicines. Pfizer has an extensive collection of documents that contain valuable data from a variety of drug development processes.

article thumbnail

Highlights from SLAS 2022 Conference - Event Recap

The Strateos Blog: Drug Discovery

Strateos’ SVP of Strategy and Operations, Daniel Sipes, gave a presentation outlining how the challenges in conventional design, make, test and analyze (DMTA) cycles in small molecule drug discovery workflows can be overcome with automated end-to-end solutions from synthesis to biological testing.